![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, March 18, 2021 12:09:31 PM
https://www.anavex.com/anavex-life-sciences-reports-anavex2-73-blarcamesine-featured-as-a-disease-modifying-small-molecule-in-phase-3-clinical-trials-in-a-new-publication-in-medical-journal-titled-future-av/
The Neuropharmacology publication noted that in the clinical study, 57 weeks of oral once daily ANAVEX®2-73 treatment showed patients improved cognition scores by +2.0 points on MMSE, a 9% mean improvement from baseline to 57 weeks, corresponding to a calculated ADAS-Cog score change of -3.4 (improvement). In these same patients ANAVEX®2-73 also improved ADCS-ADL, by +4.9 points, a 7% mean improvement from baseline to 57 weeks.
An extension of the published study (ANAVEX2-73-003) demonstrated that for the same patients at week 70 MMSE scores improved by +3.0, a 14% improvement from baseline, corresponding to a calculated ADAS-Cog score change of -5.1 (improvement). In these same patients, ANAVEX®2-73 also improved ADCS-ADL, by +6.0 points, an 8% mean improvement from baseline to 70 weeks. The mean MMSE and ADCS-ADL baseline scores for these patients in this study were 22.3 and 71.1, respectively.[4],[5]
This data seems to be consistent with the effect of ANAVEX®2-73 on cognition assessed in the recently completed placebo-controlled Phase 2 study of 132 patients with Parkinson’s disease dementia (ANAVEX2-73-PDD-001) with once-daily administration of oral 30 mg ANAVEX®2-73, 50 mg ANAVEX®2-73 and placebo for 14 weeks. The observed statistically significant improvement of CDR system Episodic Memory of +42.22 between 50 mg ANAVEX®2-73 and placebo was also dose-dependent (p = 0.003).[6] CDR system Episodic Memory has been shown to be highly correlated (70%) with the ADAS-Cog score (r = 0.7).[7]
The calculated corresponding ADAS-Cog mean change from baseline score is -1.9 (improvement) for patients in the 50 mg dose group, an 8% mean improvement from baseline to 14 weeks. The difference between the ANAVEX®2-73 group and the placebo group in the change from baseline at 14 weeks was a 4.0-point improvement of calculated corresponding ADAS-Cog score (p = 0.015).
The Mini-Mental State Exam (MMSE) and the ADAS-Cog (Alzheimer’s Disease Assessment Scale–Cognitive Subscale) are standard tests for assessing changes in cognition in Alzheimer’s disease trials and known to correlate to a high degree.[8] The ADCS-ADL (Alzheimer’s Disease Cooperative Study–Activities of Daily Living), assesses the competence of patients with Alzheimer’s disease in basic and instrumental function or activities of daily living.
Alzheimer’s is a progressive disease and over time, a patient’s cognition will always worsen. “Experience based on longitudinal studies of ambulatory patients with mild to moderate Alzheimer’s disease suggest that scores on the ADAS-cog worsen by 6-12 points per year” with the annualized rate of decline might be smaller depending on the disease stage, according to FDA’s Prescription Information sheet for ARICEPT® (donepezil), a drug approved for the treatment of dementia of the Alzheimer’s type.[9]
While the placebo-controlled 450-patient Phase 2b/3 ANAVEX®2-73 clinical study in Alzheimer’s disease is currently ongoing, prior clinical research in Alzheimer’s disease conducted by other sponsors can serve as a contextual reference for estimates of an expected rate of decline in cognition (MMSE and ADAS-Cog) and function (ADCS-ADL) in placebo patients:
In 2019, a randomized controlled trial of aducanumab (Biogen) was conducted in >1,000 patients with early Alzheimer’s disease.[10] In this Phase 3 study (EMERGE), patients on placebo showed from baseline to week 50 a mean decline in cognition of approximately -2.2 points on MMSE, an 8.3% decline, and from baseline to week 78 approximately -3.3 points on MMSE, a 12.5% decline, respectively. Mean baseline MMSE score was 26.4.
Large placebo arm data from 20 randomized controlled clinical trials including over 4500 mild-to-moderate Alzheimer’s disease patients treated with standard of care, containing ARICEPT® (donepezil, Eisai) and memantine was analyzed.[11] In this analysis, patients on placebo showed from baseline to week 52 a mean decline in cognition of approximately -2.05 points on MMSE, a 10% decline and from baseline to week 78 approximately -3.4 points on MMSE, a 16% decline, respectively, with a calculated mean baseline MMSE score of 21.0. The respective ADAS-Cog decline was 3.9 points from baseline to week 52 and a decline of 6.6 points from baseline to week 78, respectively.
A randomized controlled study including of ARICEPT® (donepezil, Eisai) and memantine was conducted in >500 patients in the placebo arm with mild-to-moderate Alzheimer’s disease.[12] In this Phase 3 study, patients on placebo showed from baseline to week 76 an estimated mean decline in cognition of approximately -3.4 points on MMSE, a 16% decline from baseline. Mean baseline MMSE score was 20.9. The mean ADAS-Cog decline was 6.4 points from baseline to week 76. The mean ADCS-ADL decline was -9.0 points from baseline to week 76.
ANAVEX®2-73 is currently in a late-stage Phase 2b/3 Alzheimer’s disease clinical trial utilizing same dosing regimen as in the above-described completed Parkinson’s disease dementia (ANAVEX2-73-PDD-001) study with differentiated patient selection criteria.[13]
“This paper highlights the relevance of the analyses of gene expression data in precision medicine to drug development that may predict increased chances of success of Alzheimer’s disease treatments, which is especially relevant in late-stage clinical studies like the ongoing ANAVEX®2-73 Phase 2b/3 clinical Alzheimer’s disease study,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
ANAVEX®2-73 activates the sigma-1 receptor (SIGMAR1). Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.[14]
Anavex Life Sciences’ product portfolio includes small molecule drug lead candidate ANAVEX®2-73 for the treatment of Alzheimer’s disease, Parkinson’s disease and Rett syndrome.
Recent SAVA News
- Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET • GlobeNewswire Inc. • 08/01/2024 12:30:00 PM
- Cassava Sciences Announces Expansion of Open-Label Extension Trials • GlobeNewswire Inc. • 07/30/2024 12:15:00 PM
- Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Cassava Sciences Issues Statement on Former Science Advisor • GlobeNewswire Inc. • 06/28/2024 07:58:09 PM
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam • GlobeNewswire Inc. • 05/10/2024 08:02:00 PM
- Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution • GlobeNewswire Inc. • 05/08/2024 03:00:00 PM
- Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ • GlobeNewswire Inc. • 05/01/2024 01:10:00 PM
- Redemption Date Announced for Warrants • GlobeNewswire Inc. • 04/15/2024 01:20:00 PM
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials • GlobeNewswire Inc. • 03/25/2024 01:13:00 PM
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference • GlobeNewswire Inc. • 03/04/2024 02:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:01:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:22:12 PM
- Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates • GlobeNewswire Inc. • 02/28/2024 02:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 02:20:27 PM
- No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months • GlobeNewswire Inc. • 02/07/2024 02:08:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 09:00:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:45 PM
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders • GlobeNewswire Inc. • 01/05/2024 02:12:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 01/03/2024 09:24:43 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 01/03/2024 09:22:52 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 01/03/2024 09:18:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 02:10:10 PM
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 02:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:19:07 PM
- Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders • GlobeNewswire Inc. • 12/12/2023 02:13:00 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM